A new survey finds that 45 percent of peptide users who bought from social media ended up in the ER — three times the rate of those who didn’t. Here’s what’s driving the crisis.
You’ve probably seen them on your feed by now — the before-and-afters, the injection tutorials, the glowing testimonials about weight loss and muscle recovery and anti-aging, all accompanied by a discount code and a “this is not medical advice” disclaimer. It’s tempting: rapid and sustained weight loss, being snatched, not thinking about food every waking minute. Peptides are indeed having a moment, and not a small one. The global peptide market has grown to more than $50 billion in annual sales and is projected to nearly double again in the next decade. But a sweeping new survey out this month puts a sharp and sobering number on what the wellness community has been reluctant to say aloud: people are getting seriously hurt — and, in disproportionate numbers, those people bought their peptides from platforms including Telegram, WhatsApp, or social media.
A new Sunlight survey of 1,000 U.S. adults who use peptides found that nearly half — 45 percent — of those who sourced their peptides from social media channels have visited the emergency room or urgent care for a peptide-related reaction. That figure is three times the rate reported by peptide users overall, where the number sits at 16 percent. One in seven of all peptide users — 14.5 percent — had bought from Telegram, WhatsApp, or social media sellers. And three in four, 75.5 percent, had turned to ChatGPT or another AI tool for dosing instructions — the kind of guidance that is supposed to come from a physician.
What makes those numbers particularly striking is the context in which the purchases happen. Social media peptide sales exist in plain sight — not hidden behind dark-web anonymity, but embedded in wellness content, community forums, and influencer channels. It is a gray market operating alongside clinical care, not outside it entirely; patients are telling their doctors about their peptide use, the survey found, even as they source their supply from sellers whose products carry no pharmaceutical oversight, no quality control, and no guarantee of purity or correct dosing.
Peptides are short chains of amino acids that occur naturally in the body, where they regulate hormones, reduce inflammation, and repair tissue. Synthetic versions are manufactured to mimic or enhance those naturally occurring proteins. The “P” in GLP-1 stands for peptide; insulin is a peptide. So the category itself is not new or inherently suspect — it is the unregulated, gray-market corner of it that is raising alarms.
The peptide boom
The GLP-1 boom is widely credited with normalizing the idea of injectable wellness compounds. “The GLP-1s put it on the map,” Evan Miller, CEO of Gameday Men’s Health, told CNN in April. “And then people were like, ‘Well, what’s next?'” Dr. Mike Mrozinski, a GP, put it plainly to the BBC: “The success of regulated GLP-1 drugs has ‘normalised’ using a needle, lowering the psychological barrier to self-injection.” What followed was a sprint toward adjacent compounds with far less regulatory guardrails — peptides like BPC-157, TB-500, and Retatrutide, none of which are approved by the FDA for human use, all of which are sold online with packaging that reads “for research purposes only.”
That legal loophole is load-bearing. Chinese manufacturers ship peptides to American consumers at scale — U.S. customs data shows imports of hormone and peptide compounds from China reached $328 million in the first three quarters of 2025, up from $164 million in the same period the year prior — and they do so under labels that function as a legal fig leaf. “When you go through the process of buying them on the websites, they’ll all say, ‘This is for research purposes only,'” Ezra Marcus, an investigative journalist who reported on the gray market for New York Magazine and spoke with NPR’s Here & Now, said. “That’s a sort of fig leaf they’re using to be able to sell these things that are obviously not for research purposes. They’re for people to inject.”
Marcus purchased a six-month supply of Retatrutide — a GLP-1 developed by Eli Lilly but not FDA-approved — directly from a Chinese factory, after finding a sales representative through a Discord server linked from Reddit. “I sent $150 in Bitcoin and received a six-month supply in the mail two weeks later,” he told NPR. No prescription, no medical history, no follow-up.
Dose problems, contamination risks
The ER visits documented in the Sunlight survey are not difficult to explain once you understand how the supply chain actually works. Products sourced from unregulated sellers carry no guarantee that what is inside the vial matches what the label says. “If you’re not testing it,” Marcus told NPR, “it’s not uncommon for the dosages to be totally wrong. They might tell you that you’ve gotten five milligrams of X, Y, and Z, but really, it’s 15 milligrams.” The consequences of an incorrect dose of a biologically active compound can range from severe nausea and kidney stones to, in at least one case Marcus documented, acute necrotizing pancreatitis — the pancreas failing entirely in a person who was taking an excessive dose of Retatrutide to lose weight for a bodybuilding competition.
Contamination is a parallel concern. An analysis by Texas testing lab Finnrick found that 8 percent of tested peptide products could be contaminated. Adam Taylor, an anatomy professor at Lancaster University, told the BBC that bacterial endotoxins can do a “serious number on you,” and described users as “converting themselves into the guinea pigs or the lab rats.” Last year, two women were hospitalized after injecting unknown peptides at a Las Vegas anti-aging festival.
What the science actually supports
The health claims circulating online about peptides — that BPC-157 heals injuries, that TB-500 speeds recovery, that various compounds reverse aging or improve cognitive function — are largely unsupported by human clinical data. Most research has been conducted in animals or laboratory settings, and the results do not transfer cleanly to human physiology or human dosing.
Paul Knoepfler, a cell and molecular biologist at the University of California, Davis, is among the scientists raising flags about BPC-157 specifically. Some animal studies suggest it helps with tissue repair by accelerating new blood vessel growth — but that same mechanism, Knoepfler explained to NPR in February, could theoretically accelerate the growth of precancerous cells. “You must test these in clinical trials to be sure of anything positive or negative,” he said. As of early 2026, only three published human studies on BPC-157 exist, and all three are small and originate from the same research group. On dosing, Knoepfler was equally direct: “You can’t just make up what dose to take. There’s often no apparent rhyme or reason to the wellness peptide doses people are taking.”
Eric Topol, director of the Scripps Research Translational Institute, told The New York Times that using unregulated peptides is “unfounded and reckless.” Howard Sklamberg, a former FDA deputy commissioner, described the current state of the peptide market to NPR with three words: “it’s really kind of a Wild West.” His counsel — and the most consistent advice from physicians across the board — is that anyone determined to explore peptide therapy should do so through a licensed physician and a compounding pharmacy, where at least some regulatory framework applies. “At least if you’re talking to your doctor,” Sklamberg told NPR, “you’re talking to somebody who can, theoretically, be held accountable.”
The accountability gap is where the Sunlight survey’s most underreported finding lives. Three in four peptide users consulted ChatGPT or another AI tool for dosing guidance — not their doctor, not a pharmacist, not a clinical trial. Community forums, Discord servers, Reddit threads, and AI chatbots have collectively assembled a shadow clinical infrastructure that, for many users, feels authoritative enough to act on. As Marcus noted, this community of peptide enthusiasts “talk to each other and say, ‘Look, I got the right thing. It gave me X, Y, and Z effect. I had it tested independently.'” The DIY quality control is real — but it is not the same as clinical oversight, and the emergency room data suggests it is not catching everything.
Dr. Amanda Kahn, who runs a concierge medical practice in New York and does prescribe peptides as adjunct therapy when she deems it appropriate, told NPR she makes sure patients understand the experimental nature of what they’re taking. “I don’t overpromise that this is a cure-all,” she said. That kind of physician-level honesty is precisely what a Telegram seller is not offering — and, it turns out, neither is an AI chatbot.
Related on Ethos:
